Analysts expect Obalon Therapeutics, Inc. (NASDAQ:OBLN) to report $-0.48 EPS on February, 22.They anticipate $0.03 EPS change or 5.88% from last quarter’s $-0.51 EPS. After having $-0.55 EPS previously, Obalon Therapeutics, Inc.’s analysts see -12.73% EPS growth. The stock increased 5.22% or $0.21 during the last trading session, reaching $4.23. About 135,776 shares traded. Obalon Therapeutics, Inc. (NASDAQ:OBLN) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.
AC Immune SA (NASDAQ:ACIU) had a decrease of 1.19% in short interest. ACIU’s SI was 1.74 million shares in February as released by FINRA. Its down 1.19% from 1.76 million shares previously. With 37,500 avg volume, 46 days are for AC Immune SA (NASDAQ:ACIU)’s short sellers to cover ACIU’s short positions. The SI to AC Immune SA’s float is 8.06%. The stock increased 0.60% or $0.07 during the last trading session, reaching $11.79. About 304,872 shares traded or 249.70% up from the average. AC Immune SA (NASDAQ:ACIU) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.
Among 2 analysts covering Obalon Therapeutics (NASDAQ:OBLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Obalon Therapeutics had 2 analyst reports since October 31, 2016 according to SRatingsIntel. The rating was initiated by Stifel Nicolaus on Monday, October 31 with “Buy”. The firm has “Buy” rating by UBS given on Monday, October 31.
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The company has market cap of $73.78 million. It offers the Obalon balloon system designed to provide weight loss in obese patients. It currently has negative earnings.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $671.11 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases. It currently has negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.